Drilling down on drug prices

<?xml version="1.0" encoding="UTF-8"?><modsCollection xmlns="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-8.xsd">
<mods version="3.8">
<titleInfo>
<title>Drilling down on drug prices</title>
</titleInfo>
<name type="personal" usage="primary" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20190009621">
<namePart>Passwater, Keith</namePart>
<nameIdentifier>MAPA20190009621</nameIdentifier>
</name>
<name type="personal" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080051983">
<namePart>Nelson, Dave</namePart>
<nameIdentifier>MAPA20080051983</nameIdentifier>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="marcgt">periodical</genre>
<originInfo>
<place>
<placeTerm type="code" authority="marccountry">usa</placeTerm>
</place>
<dateIssued encoding="marc">2019</dateIssued>
<issuance>serial</issuance>
</originInfo>
<language>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<form authority="marcform">print</form>
<extent>8 p. </extent>
</physicalDescription>
<abstract displayLabel="Summary">Extending life and improving quality of life for literally millions, drug treatments such as aspirin, penicillin, insulin, AZT, cancer drug Herceptin, Harvoni, and Lipitor are nothing short of miracle drugs. Recently developed therapies are also impressive, such as single-dose Kymriah, which has an unprecedented 83 percent remission rate for children with acute lymphoblastic leukemia.[1] Another example is the newly available gene therapy Luxturna, which can cure blindness in carefully selected patients. Such therapies can achieve outcomes that are truly miraculous for those cured patients; they can also be staggeringly expensive. While anyone with a heart would agree that these miracle drug benefits are wonderful for patients, we need to find ways to harness these invaluable benefits while also finding ways to curb the growth in drug costs in the U.S. for all partiesconsumers, payers, and manufacturers alike. </abstract>
<note type="statement of responsibility">Keith Passwater, Dave Nelson</note>
<subject xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080606633">
<topic>Industria farmacéutica</topic>
</subject>
<subject xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080579784">
<topic>Costes económicos</topic>
</subject>
<subject xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080621919">
<topic>Precios de los medicamentos</topic>
</subject>
<classification authority="">931</classification>
<relatedItem type="host">
<titleInfo>
<title>Contingencies : American Academy of Actuaries</title>
</titleInfo>
<originInfo>
<publisher>Washington : American Academy of Actuaries, 2019-2024</publisher>
</originInfo>
<identifier type="local">MAP20190020794</identifier>
<part>
<text>07/05/2019 Año 2019 - May-June , p. 38-45</text>
</part>
</relatedItem>
<recordInfo>
<recordContentSource authority="marcorg">MAP</recordContentSource>
<recordCreationDate encoding="marc">190710</recordCreationDate>
<recordChangeDate encoding="iso8601">20190715150850.0</recordChangeDate>
<recordIdentifier source="MAP">MAP20190021326</recordIdentifier>
<languageOfCataloging>
<languageTerm type="code" authority="iso639-2b">spa</languageTerm>
</languageOfCataloging>
</recordInfo>
</mods>
</modsCollection>